Vanja Sikirica

Vanja Sikirica is an experienced health outcomes research professional currently serving as Executive Director of Epidemiology, HEOR & Patient Centered Outcomes at Moderna, responsible for leading the evaluation and development of epidemiological and health economics strategies for mRNA technologies. Prior roles include Senior Director positions at Pfizer, GSK, and Shire, where Vanja oversaw pipeline assets and the integration of health economics, reimbursement strategies, and patient-centered outcomes in various therapeutic areas such as oncology, immunology, cardiovascular, and rare diseases. Vanja's educational background includes a Pharm.D. from the University of Maryland and an MPH in Epidemiology from Johns Hopkins University, complemented by fellowships and internships in epidemiology and health outcomes.